Fig. 1: ELISA reactivity and binding inhibitory activity of sera from volunteers after immunization with protein-in-adjuvant or viral-vectored PvDBPII vaccines. | npj Vaccines

Fig. 1: ELISA reactivity and binding inhibitory activity of sera from volunteers after immunization with protein-in-adjuvant or viral-vectored PvDBPII vaccines.

From: PvDBPII elicits multiple antibody-mediated mechanisms that reduce growth in a Plasmodium vivax challenge trial

Fig. 1: ELISA reactivity and binding inhibitory activity of sera from volunteers after immunization with protein-in-adjuvant or viral-vectored PvDBPII vaccines.

a ELISA titres for recognition of PvDBPII SalI by sera from volunteers at different timepoints over the course of the trial reported as median and range for each vaccine group are shown. Black arrows show the time points of the immunizations. Shaded grey areas represent the period after blood stage P. vivax challenge. b ELISA recognition titres and binding inhibition titres for PvDBPII variants SalI and PvW1 for all volunteers at C-2. Medians are shown in horizontal bars, **p < 0.01, Kruskal–Wallis test with Dunn’s correction for multiple comparisons.

Back to article page